The properties of the drug may be altered by the combination, which may cause unexpected
drug–drug interactions (DDIs). Prediction of DDIs provides combination strategies of drugs …

Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients
is increased and often requires treatment or prophylaxis with direct oral anticoagulants …

Many computational methods have been proposed to predict drug–drug interactions (DDIs),
which can occur when combining drugs to treat various diseases, but most mainly utilize …

Importance Clinical trial sponsors rely on eligibility criteria to control the characteristics of
patients in their studies, promote the safety of participants, and optimize the interpretation of …

Drug combination therapies are common practice in the treatment of cancer, but not all
combinations result in synergy. As traditional screening approaches are restricted in their …

Background The aim of this study was to determine the drug profile of patients with non-
small cell lung cancer (NSCLC) and to identify potential drug–drug interactions (PDDIs) …

Objective: A LUNGevity Foundation working group developed a framework for lung cancer
clinical trial eligibility criteria. The goals of this framework are to (1) simplify eligibility …

Background: Cancer patients are more vulnerable to developing drug-drug interactions as
multiple medications are administered concomitantly with cytotoxic agents to treat the …

Polypharmazie erhöht das Risiko von Arzneimittelinteraktionen und Medikationsfehlern. In
dieser Studie wurde die Prävalenz von potentiell ungeeigneten Medikamenten (PIMs) …

Objective: The use of multiple medications in cancer patients is unavoidable; thus, adverse
drug-drug interactions are frequent. This study aims to assess the prevalence of potential …